# HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health

> **NIH ALLCDC U01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2022 · $899,999

## Abstract

ABSTRACT
Lupus remains a leading cause of death in young women, with racial/ethnic minority patients having worse
long-term outcomes, including progression to end stage renal disease and overall mortality, and poorer
intermediate outcomes of disease activity and damage accrual. Further, manifestations of lupus affect physical
function, fatigue, pain, and other patient-reported outcomes, potentially leading to challenges with maintaining
everyday activities and function, which are linked to better quality of life, productivity, and survival. Finally, a
major challenge in SLE management is delayed identification of early kidney disease, which ultimately leads to
a greater burden on both patients and the health system. In response to the CDC NOFO RFA-DP-22-002,
Component A, “Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts,” this proposal
leverages our well-established, longitudinal, ethnically/racially and socioeconomically diverse, and
phenotypically well-characterized cohort of patients with lupus. This proposal’s overarching goals include
clarifying the long-term natural history of SLE by evaluating disease severity, morbidity, and multi-morbidity;
assessing disparities in illness experience associated with race/ethnicity, age, and socioeconomic status;
collecting novel biospecimens to potentially differentiate roots of pain/fatigue syndromes; and evaluating a
novel strategy to identify early kidney disease in high-risk patients. The NYU Lupus Cohort is a “living”
biorepository with >900 patients enrolled, three-quarters followed at least twice annually, with diverse
backgrounds (50% minority race; 30% Hispanic) and socioeconomic status (31% public hospital patients) who
provide samples over time. Data include demographics, established classification criteria over time,
medications, routine metabolic and hematologic parameters, laboratory-based urine analysis, autoantibody
profiles, disease activity fluctuations and organ damage accrual using validated instruments, patient-reported
outcomes, and measures for socioeconomic status and position, and material, behavioral, psychosocial, health
system, and health outcomes. We propose to extend our longitudinal Cohort with linkage to electronic health
records and state-wide, all-payer claims data for comorbidity data, new cytokine profiles and transcriptomic
modules, and implementating a novel strategy to identify early kidney disease. Our multidisciplinary team will
address three Specific Aims: 1) Quantify multimorbidity and major healthcare use in patients with lupus to
improve understanding of lupus and non-lupus comorbidities, including disparities by sociodemographic
factors; 2) Measure the burden of lupus on quality of life, with analyses to assess disparities by
sociodemographic factors, behavioral and psychosocial factors, and genetic information; and 3) Develop and
evaluate innovative, technology-driven home-based proteinuria testing for patients at elevated risk of neph...

## Key facts

- **NIH application ID:** 10552857
- **Project number:** 1U01DP006700-01
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Jill P Buyon
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** ALLCDC
- **Fiscal year:** 2022
- **Award amount:** $899,999
- **Award type:** 1
- **Project period:** 2022-09-30 → 2027-09-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10552857

## Citation

> US National Institutes of Health, RePORTER application 10552857, HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health (1U01DP006700-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10552857. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*